Abiopharma

🔍 Doyle Mittie (Executive)

Company: Avalo Therapeutics, Inc. (AVTX)

Report Date: 2026-08-17

Detailed Transactions and Holdings:

• Acquired 1,000 shares of Common Stock at $12.65 per share (Direct)
  Date: 2026-08-17 | Code: M | equity_swap_involved: 0 | shares_owned_after: 52,776.00 | transaction_form_type: 4 | Footnotes: F1
• Sold 1,000 shares of Common Stock at $20.0 per share (Direct)
  Date: 2026-08-17 | Code: S | equity_swap_involved: 0 | shares_owned_after: 51,776.00 | transaction_form_type: 4 | Footnotes: F1
• Sold 1,000 shares of Stock Option (Right to Buy) at $12.65 per share (Derivative)
  Date: 2026-08-17 | Code: M | Expires: 2034-07-15 | equity_swap_involved: 0 | shares_owned_after: 123,750.00 | transaction_form_type: 4 | Footnotes: F1, F2

Footnotes:

• F1: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 13, 2025.
• F2: The stock option vests twenty-five percent (25%) on July 15, 2025 and the remainder will vest in equal monthly installments over the following three (3) years, subject to the Reporting Person's continued service on each such vesting date.